New York City, USA – With cases of mpox on the rise in the United States, health experts are sounding the alarm about the importance of increasing vaccination coverage to curb transmission risks. Reported cases have more than doubled compared to this time last year, reaching 511 cases by mid-March, according to data from the US Centers for Disease Control and Prevention. While transmission rates remain lower than the peak seen in 2022, experts warn that the country is susceptible to a resurgence due to decreased federal resources and relatively low vaccination rates.
In a recent health alert, the CDC warned healthcare providers about a more transmissible subtype of the virus that has been circulating in the Democratic Republic of Congo. Dr. Marcus Plescia, chief medical officer for the Association of State and Territorial Health Officials, emphasized the importance of vaccination in preventing outbreaks of mpox. While the virus, a cousin of smallpox, can cause flu-like symptoms and skin lesions, vaccination with the two-dose regimen of Jynneos has been proven effective in offering long-term protection.
Despite the availability of the vaccine, data from the CDC shows that less than a quarter of the at-risk population in most states have been fully vaccinated. This comes as various regions across the US report an increase in cases, with the mid-Atlantic region, especially New York City, experiencing a notable surge. The Virginia Department of Health issued a notice to raise awareness about the rise in cases in the state, emphasizing the importance of vaccination ahead of Pride season.
Experts stress the need for targeted efforts to reach at-risk populations, particularly men who have sex with men and those with HIV. While behavior changes have had a positive impact on reducing transmission, vaccination remains a crucial and sustainable measure for prevention. Looking ahead, experts highlight the need for continued access to vaccination and treatment to address the challenges posed by mpox and other sexually transmitted diseases.
As the federal government transitions the management of mpox vaccines to commercial systems, there are concerns about the visibility of vaccination rates and potential shortages. Elizabeth Finley, senior director of communications and prevention programs with the National Coalition of STD Directors, points out the challenges in accessing treatment, underscoring the importance of preventive measures. With increasing pressures on sexual health programs, a collaborative effort is needed to address the complex issues surrounding mpox and other diseases.